Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization

Raskin GA, Mukhina MS, Kravtsova ED, et al. . Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization. Russian Journal of Archive of Pathology. 2023;85(3):40‑45. (In Russ.)
https://doi.org/10.17116/patol20238503140

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

BACKGROUND

Assessment of FGFR2 status in gastric cancer is an important task, without clarification of which it is impossible to identify a cohort of patients in whom the best response to treatment with anti-FGFR2 drugs could be obtained.

OBJECTIVE

To conduct a comparative analysis of the expression and amplification of the FGFR2 gene in gastric cancer in primary tumors and metastases in the lymph nodes.

MATERIAL AND METHODS

FGFR2 status was studied in 61 patients with stage III gastric adenocarcinoma using an immunohistochemical method (Abcam clone EPR24075-418, R&D clone 98706, Santa Cruz clone C-8, Abcam clone 1G3) and FISH.

RESULTS

The antibody Abcam clone EPR24075-418 was found satisfactory for the immunohistochemical study of FGFR2. FGFR2 expression was detected in 26 (43%) cases, amplification in 5 (8%) cases. Amplification of FGFR2 in 4 cases out of 5 was accompanied by the expression of 3+, in 1 case — 2+. Discordance between FGFR2 expression in primary tumor and lymph node metastases was revealed in 13 (21%) cases.

CONCLUSION

Clone EPR24075-418 showed the best result in assessing the expression of FGFR2: the correlation with FISH results in reaction 3+ was 100%. Due to the high heterogeneity of FGFR2 expression, it is recommended to either examine the material of the primary tumor and metastasis, or evaluate a large volume of the primary tumor.

Keywords:

FGFR2

gastric cancer

heterogeneity

Authors:

Raskin G.A.

Dr. Berezin Medical Institute;
Saint-Petersburg State University

ORCID: 0000-0002-7522-6552

Mukhina M.S.

Dr. Berezin Medical Institute

ORCID: 0000-0002-3735-6145

Kravtsova E.D.

Dr. Berezin Medical Institute

ORCID: 0000-0003-1920-9798

Timofeev I.V.

S.M. Kirov Military Medical Academy

ORCID: 0000-0001-9663-0995

Tyulandin S.A.

N.N. Blokhin National Medical Research Center of Oncology

ORCID: 0000-0001-9807-2229

Belyak N.P.

Saint-Petersburg State University;
Saint Petersburg City Clinical Oncology Dispensary

ORCID: 0000-0003-0402-6067

Kleshchev M.A.

Saint Petersburg City Clinical Oncology Dispensary

ORCID: 0000-0002-7537-2525

Orlova R.V.

Saint-Petersburg State University;
Saint Petersburg City Clinical Oncology Dispensary

ORCID: 0000-0003-4447-9458

Received:

11.01.2022

Accepted:

22.02.2023

Close metadata

References:

Katoh M, Katoh M. FGF signaling network in the gastrointestinal tract (review). Int J Oncol. 2006;29:163-168.
Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139-149. https://doi.org/10.1016/j.cytogfr.2005.01.001
Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11): 1430-1440. https://doi.org/10.1016/S1470-2045(22)00603-9
Ishiwata T. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Front Biosci (Landmark Ed). 2018; 23(4):626-639. https://doi.org/10.2741/4609
Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013;19(9):2572-2583. https://doi.org/10.1158/1078-0432.CCR-12-3898
Das K, Gunasegaran B, Tan IB, Deng N, Lim KH, Tan P. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. Cancer Lett. 2014;353(2): 167-175. https://doi.org/10.1016/j.canlet.2014.07.021
Inokuchi M, Murase H, Otsuki S, Kawano T, Kojima K. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer. World J Surg Oncol. 2017;15(1):2. https://doi.org/10.1186/s12957-016-1081-4
Tokunaga R, Imamura Y, Nakamura K, Ishimoto T, Nakagawa S, Miyake K, Nakaji Y, Tsuda Y, Iwatsuki M, Baba Y, et al. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget. 2016;7(15):19748-19761. https://doi.org/10.18632/oncotarget.7782
Hosoda K, Yamashita K, Ushiku H, Ema A, Moriya H, Mieno H, Washio M, Watanabe M. Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy. Oncol Lett. 2018;15(2):1853-1860. https://doi.org/10.3892/ol.2017.7515
Park YS, Na YS, Ryu MH, Lee CW, Park HJ, Lee JK, Park SR, Ryoo BY, Kang YK. FGFR2 assessment in gastric cancer using quantitative real-time polymerase chain reaction, fluorescent in situ hybridization, and immunohistochemistry. Am J Clin Pathol. 2015;143(6):865-872. https://doi.org/10.1309/AJCPNFLSMWWPP8DR
Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, et al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020;38(21):2418-2426. https://doi.org/10.1200/JCO.19.01834
Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, et al. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer. 2016;61:20-28. https://doi.org/10.1016/j.ejca.2016.03.068
Tsimafeyeu I, Vladimirova LYu, Mochalova A, Besova N, Statsenko G, Rykov I, Utyashev IA, Raskin G, Kazey V, Artamonova E, et al. Alofanib in subsequent therapy for advanced gastric cancer: final results from the phase Ib clinical trial. J Clin Oncol. 2022;40(16 suppl):e16077. https://doi.org/10.1200/JCO.2022.40.16_suppl.e16077
Raskin G, Kazey V, Gorbacheva S, Nikiforova A, Statsenko G, Artamonova E, Vladimirova L, Besova N, Mochalova A, Rykov I, et al. Abstract 3481: Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: a phase 1b study. Cancer Res. 2022;82(12 suppl):3481. https://doi.org/10.1158/1538-7445.AM2022-3481
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94. https://doi.org/10.1038/nrclinonc.2017.166
Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L. HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice. World J Gastroenterol. 2016;22(26):5879-5887. https://doi.org/10.3748/wjg.v22.i26.5879
Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G, Jiang W, Sheng W, Wang L. Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int. 2020;20:186. https://doi.org/10.1186/s12935-020-01273-0
Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 2016;6(8):838-851. https://doi.org/10.1158/2159-8290.CD-15-1246